Article Text

Download PDFPDF
Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Statistics from Altmetric.com

Footnotes

  • Competing interests HT has received fellowship grants from the Canadian Institutes of Health Research (CIHR), Centre for Addiction and Mental Health (CAMH) Foundation, the Japanese Society of Clinical Neuropsychopharmacology and Astellas Foundation for Research on Metabolic Disorders, and manuscript fees from Dainippon Sumitomo Pharma. GR has received research support from Novartis, Medicure and Neurocrine Bioscience, as a co-investigator he has received grant support from Pfizer Inc, consultant fees from Laboratorios Farmacéuticos ROVI, Synchroneuron, Novartis and Roche and speaker's fees from Novartis.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.